full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for March, 2014

28
Mar

After two FDA rejections, MannKind has returned with more data on its long-delayed inhaled diabetes drug, but regulators see Afrezza as anything but a slam-dunk case, raising questions over the treatment’s safety and efficacy before a scheduled review. …read more Source: MannKind faces stiff skepticism in its third go at FDA approval     

27
Mar

Denmark’s Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson. …read more Source: Genmab banks $22M from J&J as myeloma drug ticks forward     

27
Mar

Baxter International is the latest life sciences player to see better living through mitosis, unveiling a plan to separate its drug development arm from its sprawling med tech business in hopes of helping each grow faster. …read more Source: UPDATED: Baxter breaks in two, creating a $6B biotech business     

27
Mar

As more and more drugmakers set sights on China through partnerships and acquisitions, Sino-American biotech RuiYi is taking a more direct approach, raising $15 million in venture cash to develop novel drugs in the country, for the country. …read more Source: RuiYi banks $15M from A-list backers to amp up Chinese R&D     

26
Mar

Fresh off starting up its first clinical trial, New Haven, CT’s Kolltan Pharmaceuticals has wrapped up a $60 million D round, filling its coffers as it prepares for the developmental long haul with a cancer candidate. …read more Source: Kolltan banks $60M to hit the gas on its cancer drug     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off